A different road from everyone else here
Every other seller on these boards is built around cash-pay compounded medication. Zealthy is built around getting an FDA-approved product covered by your plan.
Coordinators work the coverage process on the patient side rather than handing prior authorization back to you. For a reader who has already been through a denial, that is the whole pitch.
It also makes Zealthy hard to compare on a price table. Its headline is not a price a seller sets. It is what a patient pays after an insurer agrees to cover a drug, which is a different kind of number entirely.
The condition attached to the headline figure
Zealthy's lowest advertised figure applies only once insurance coverage is obtained. Its own page frames it that way, describing a reduction from a list price down to that figure through coverage.
If your plan declines, that number does not apply to you. The cash-pay compounded figure applies instead, and the distance between the two is very large.
The cash-pay rate carries a condition of its own: it assumes buying a quarter at a time rather than a month. So both of Zealthy's published figures are conditional, in different ways.
Price Zealthy at the cash-pay figure first. If coverage comes through, the outcome is better than anything else in this comparison. If it does not, that is the number you were always going to pay.
The FDA warning letter, and what it was about
The company behind Zealthy received an FDA warning letter in February 2026. The letter is public, and it names the same company and the same New York address that appear in Zealthy's own terms.
It concerns website claims. The agency reviewed content on a different site the company operated and found the claims there about compounded semaglutide and tirzepatide false or misleading under the misbranding sections of the federal act.
That is a marketing and labeling finding. It is not evidence that a medication was contaminated, ineffective or unsafe, and it is not read that way here. It does not move Zealthy's score or its position on any board.
It is still worth knowing. A regulator has told this company that its promotional claims went too far, so read its marketing with that in mind and ask for specifics in writing.
Who Zealthy is, on paper
Zealthy's terms name the operating company and state that it trades under the Zealthy name. The site footer separately shows a differently named corporate entity.
That split is worth noticing because the warning letter was issued to the operating company, not to the brand. A reader searching the brand name alone would not find it.
Both names, and the address behind them, are published on Zealthy's own pages. The disclosure is there; it just takes a moment to line up.
What is missing
Zealthy does not name the compounding pharmacy behind its cash-pay option. That is the same gap most of this field has.
No list of served states appears on the weight-loss page. Coverage-dependent pricing makes state and plan questions more consequential than usual, so confirm both directly.
The promotional banner running on the weight-loss page is a discount rather than a rate, and it should not be added into a comparison as if it were one.
Zealthy's published pricing
compareglp may earn a commission when a reader signs up with a provider through a link on this site. None of the 16 providers reviewed here are paid partners today. See how this works.
See Zealthy's current price →Good fit if
- Patients with insurance who want help getting a brand-name GLP-1 covered rather than paying cash for a compounded one.
- Readers who have already been denied coverage and want someone else working the appeal.
- People who would rather take an FDA-approved finished drug than a compounded preparation, if coverage can be arranged.
- Readers who will price the cash-pay fallback first and treat the insured figure as the good outcome rather than the expected one.
Look elsewhere if
- Anyone without insurance, or whose plan excludes weight-loss medication. The insured figure will not apply, and the cash-pay figure is far higher.
- Readers who want a fixed monthly price they can plan around. Both of Zealthy's published figures are conditional.
- Patients who want a company with no regulatory history in its file, since the operating entity received a warning letter about marketing claims in February 2026.
- Readers who need the compounding pharmacy named or their state confirmed from the site.
How this review was verified
- Read Zealthy's weight-loss page at its source URL and logged both published figures with the date each was read.
- Carried each figure's condition into its qualifier: the low figure applies only once coverage is secured, and the cash-pay figure assumes a quarterly purchase.
- Confirmed the operating entity and its address from Zealthy's own terms of use, and noted the separate corporate name shown in the site footer.
- Read the FDA warning letter at the agency's own site rather than from a summary, and confirmed the recipient address matches the one published in Zealthy's terms.
- Read what the letter actually alleges. It concerns claims made on a different website the company operated, under the misbranding provisions, and it is reported as a marketing finding rather than a safety one.